The monitoring plan (also: monitoring concept) is a study-specific document that describes how, when, where, and by whom the clinical monitoring of a study is conducted. It is based on a previously performed risk analysis and defines which monitoring activities—on-site visits, remote monitoring, central monitoring—will take place, to what extent, and according to which schedule. The monitoring plan is a mandatory document according to ICH E6(R2) and EU Regulation 536/2014 and must be finalized and filed in the Trial Master File before study initiation. It forms the operational basis for the entire monitoring team and ensures that all stakeholders have a uniform understanding of the monitoring strategy. The plan also describes how deviations are documented, communicated, and resolved, and establishes the standards for quality assessment of study conduct.
Regulatory Basis
ICH E6(R2) has fundamentally changed the requirements for the monitoring plan with the introduction of risk-based monitoring (RBM). Instead of purely visit-based oversight, the guideline now requires that the monitoring scope be based on a systematic risk assessment. The EMA has published supplementary guidelines on risk-based monitoring (EMA/INS/GCP/394194/2011), and the FDA has issued corresponding guidance (FDA Guidance on Risk-Based Monitoring, 2019). Both authorities emphasize that the monitoring plan is a living document that must be updated when risk conditions change.
In EU Regulation 536/2014, the sponsor’s monitoring responsibility is anchored in Article 48. The sponsor must ensure that monitoring is performed by qualified personnel who are independent of the investigational sites. The responsibility may be delegated to a CRO, but remains legally with the sponsor. During GCP inspections by national authorities or the EMA, the monitoring plan is one of the first documents requested. A missing, incomplete, or non-updated monitoring plan is considered a critical GCP finding.
Content and Structure of the Monitoring Plan
A complete monitoring plan contains at least the following components: A description of the risk assessment methodology and the identified study risks. The derived monitoring strategy with the allocation between on-site monitoring, remote monitoring, and central monitoring. The planned monitoring scope per investigational site, expressed in visit frequency, SDV rate (Source Data Verification), and data points to be monitored. The roles and qualification requirements of the monitoring team as well as clear escalation pathways in case of deviations. Schedules for regular monitoring visits (Site Initiation Visit, Interim Monitoring Visits, Site Close-out Visit) as well as criteria for unscheduled visits.
Increasingly, Key Risk Indicators (KRIs) and Key Performance Indicators (KPIs) are also defined in the monitoring plan, based on which the quality of study conduct is continuously monitored. These metrics enable early detection of anomalies and targeted intervention before they affect data quality. Typical KRIs include protocol deviation rates, time delays in data entry, and rates of missing informed consent forms. The definition of these thresholds must be documented and justified in the monitoring plan. Continuous evaluation of KRIs allows dynamic adjustment of the monitoring scope during the course of the study and is therefore an essential component of the risk-based approach.
Risk-Based Monitoring in Practice
Implementation of a risk-based monitoring plan requires careful preliminary analysis of study-related risks: protocol complexity, investigational site experience, criticality of endpoints, patient safety aspects, and regulatory requirements all factor into the risk classification. High-risk data points—for example, primary endpoints, informed consent forms, and safety data—receive intensive oversight, while low-risk data can be monitored remotely or centrally. This prioritization saves resources while simultaneously increasing focus on what is essential.
In practice, a well-designed monitoring plan not only ensures regulatory compliance but also improves overall study quality. Investigational sites with clear expectations regarding the type and frequency of oversight work more efficiently, and problems are identified earlier. Full-service CROs such as mediconomics develop study-specific monitoring plans based on proven risk models and ensure that the monitoring strategy complies with regulatory requirements at all times.
Responsibilities and Delegation
The monitoring plan definitively specifies who is responsible for which monitoring task. This includes designation of the Lead Clinical Research Associate (Lead CRA) as well as backup monitors for individual investigational sites. If the sponsor transfers monitoring tasks to a CRO, this must be documented in a separate delegation letter and in the monitoring plan. Qualification requirements, training history, and assignment of monitors to sites are mandatory components.
Furthermore, the monitoring plan describes the communication pathways between monitor, investigational site, and sponsor. Escalation pathways for major protocol deviations, adverse events with reporting obligations, and data quality issues must be clearly defined. A well-structured escalation process shortens response times and prevents problems from remaining undetected. Communication between monitor and investigational site typically occurs via standardized contact reports, whose format and content are specified in the monitoring plan.
Frequently Asked Questions (FAQ)
Must the Monitoring Plan Be Available Before Study Initiation?
Yes. According to ICH E6(R2) and EU Regulation 536/2014, the monitoring plan must be finalized and available in the Trial Master File before the first site initiation visit. Retrospective preparation constitutes a GCP violation and may be cited during inspections.
Can the Monitoring Plan Be Changed During the Study?
Yes, and this is explicitly intended. Changes should be based on modified risk assessments—for example, following anomalies in KRI evaluations or after protocol amendments. All changes must be documented, justified, and archived in the TMF.
What Is the Difference Between Monitoring Plan and Monitoring Report?
The monitoring plan describes the planned approach. Monitoring reports (visit reports) document the activities actually performed during each visit or remote monitoring cycle. Both documents are mandatory components of the Trial Master File and are reviewed during inspections.